Program
tebapivat
Also written as “Tebapivat”, “[14C]-tebapivat” and “[13C2,15N3]-tebapivat”.
Its studies are mostly in Anemia, Sickle Cell · Myelodysplastic Syndromes, led by Agios Pharmaceuticals.
Furthest: phase 2, since Jul 26, 20224 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 42 open or running | phase 2since Jul 26, 2022 | Jul 15, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 15, 2020First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04536792 · 122 enrolled · United States, Denmark, Spain
- Jul 26, 2022Phase 2 study in Myelodysplastic SyndromesNCT05490446 · 87 enrolled · United States, Australia, Austria and more
- Dec 17, 2024Phase 1 study in Healthy ParticipantsNCT06745271 · 8 enrolled · United States
- Apr 10, 2025Phase 2 study in Anemia, Sickle CellNCT06924970 · 59 enrolled · United States, Belgium, Canada and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06924970Anemia, Sickle Cell · United States, Belgium, Canada and more | 2 | Active, not recruiting | May 12, 2026 | 59 |
| NCT06745271Healthy Participants · United States | 1 | Completed | Feb 21, 2025 | 8 |
| NCT05490446Myelodysplastic Syndromes · United States, Australia, Austria and more | 2 | Active, not recruiting | Mar 17, 2026 | 87 |
| NCT04536792Anemia, Sickle Cell · United States, Denmark, Spain | 1 | Completed | Dec 19, 2023 | 122 |
How it is read
Names in the registry
- “Tebapivat”, 2 entries
- “[14C]-tebapivat”, 1 entry
- “[13C2,15N3]-tebapivat”, 1 entry
- “AG-946”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 2 studies
- Myelodysplastic Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.